Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 11,156 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohort study Clear all
Recruiting Phase 2 Interventional

Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

NCT07199764
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Odetiglucan, Mitazalimab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 29, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide

NCT06972992
View directory record Official record
Conditions
Chronic Weight Management
Interventions
ASC47 +Semaglutide, Placebo+Semaglutide
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 29, 2026, 9:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Volunteer Screening for Vaccine and Antivirals Clinical Trials

NCT01593709
View directory record Official record
Conditions
Normal Physiology
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 29, 2026, 9:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

NCT06270316
View directory record Official record
Conditions
Fabry Disease
Interventions
AMT-191
Drug
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 29, 2026, 9:57 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin

NCT02206100
View directory record Official record
Conditions
Healthy
Interventions
PER977, Placebo, enoxaparin
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 29, 2026, 9:57 PM EDT
Completed Phase 2 Interventional

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

NCT00718692
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Sym001
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Omaha, Nebraska • Philadelphia, Pennsylvania • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 29, 2026, 9:57 PM EDT
Recruiting Not applicable Interventional

Forceps vs. Snare IVC Filter Removal

NCT04092192
View directory record Official record
Conditions
DVT
Interventions
IVC filter removal
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 29, 2026, 9:57 PM EDT
Completed No phase listed Observational

LONGEVITY Study. Evaluation of the Device and Battery Longevity of Boston Scientific Market-released ICD and CRT-D Devices

NCT02091011
View directory record Official record
Conditions
Implantable Cardioverter Defibrillators, CRT-D Cardiac Resynchronization Therapy Defibrillator
Interventions
Not listed
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
51
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 29, 2026, 9:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity

NCT00528944
View directory record Official record
Conditions
Emphysema
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 81 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 29, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Aging on Primary and Secondary Vaccine Responses

NCT03312699
View directory record Official record
Conditions
Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions
Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 29, 2026, 9:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lean Muscle Function

NCT01616498
View directory record Official record
Conditions
Single Muscle Fibers
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
65 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 29, 2026, 9:57 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

NCT04604132
View directory record Official record
Conditions
Gastric Adenocarcinoma
Interventions
Derazantinib, Derazantinib-paclitaxel-ramucirumab combination
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Orlando, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 29, 2026, 9:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

NCT02520063
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Everolimus, TRC105
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 29, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label, 2 Treatment Period,Study To Study The Drug Interaction Between Repeated Doses Of Itraconazole And Single Dose Pharmacokinetics (PK) Of PF-06648671 In Healthy Adults.

NCT02883114
View directory record Official record
Conditions
Healthy
Interventions
PF-06648671, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 29, 2026, 9:57 PM EDT
Completed Not applicable Interventional

SmartCPR Trial: An Analysis of a Waveform-Based Automated External Defibrillation (AED) Algorithm on Survival From Out-of-Hospital Ventricular Fibrillation

NCT00535106
View directory record Official record
Conditions
Ventricular Fibrillation, Cardiac Arrest
Interventions
Automated external defibrillator (Philips FR2+ AED), SmartCPR, Delayed defibrillation
Device · Other
Lead sponsor
New York City Fire Department
Government
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2009 · Synced Oct 29, 2026, 9:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

NCT01302847
View directory record Official record
Conditions
HIV Infections
Interventions
DTG film-coated tablets, DTG granules for suspension, DTG dispersible tablets
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Weeks to 17 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
17
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 29, 2026, 9:57 PM EDT
Not listed Phase 2 Interventional

MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

NCT02137759
View directory record Official record
Conditions
Glioblastoma Multiforme of Brain
Interventions
Standard Radiation Therapy, Standard Temozolomide, Belinostat
Radiation · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 29, 2026, 9:57 PM EDT
Active, not recruiting No phase listed Observational

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

NCT07215962
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Nivolumab + ipilimumab, Nivolumab + ipilimumab + platinum-based chemotherapy, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy, Other dual-immuno-oncology therapy with chemotherapy
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fleming Island, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 29, 2026, 9:57 PM EDT
Recruiting Phase 2Phase 3 Interventional

Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH

NCT02716246
View directory record Official record
Conditions
MPS IIIA, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis III
Interventions
UX111, Prophylactic Immunomodulatory (IM) Therapy, Optimized Prophylactic IM Therapy, Adjuvant IM Therapy
Biological · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 29, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses

NCT01998646
View directory record Official record
Conditions
Pharmacokinetics of ASP4058, Healthy Subjects, Food Effect of ASP4058
Interventions
ASP4058, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Miami, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Oct 29, 2026, 9:57 PM EDT
Terminated Phase 1 Interventional

Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study

NCT03748303
View directory record Official record
Conditions
Alzheimer Dementia
Interventions
Allopregnanolone
Drug
Lead sponsor
University of Arizona
Other
Eligibility
55 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 29, 2026, 9:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

NCT06372210
View directory record Official record
Conditions
Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
Interventions
Placebo IEM tablet, Abilify MyCite®, D-Tect Patch
Drug · Device
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 29, 2026, 9:57 PM EDT
Recruiting Phase 2 Interventional Results available

Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

NCT04304820
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Eltrombopag, Cyclosporine, Horse-Anti-thymocyte-Globulin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
3 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 29, 2026, 9:57 PM EDT
Recruiting Not applicable Interventional

Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure

NCT02464696
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Methylprednisolone, Oxygen Therapy, Positive Air Pressure Device
Drug · Procedure · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 9:57 PM EDT